Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk

Oncology

Volumn 75, Issue 3-4, 2008, Pages 215-223

  Kabbinavar, Fairooz ^a   Irl, Cornelia ^c   Zurlo, Alfredo ^c   Hurwitz, Herbert ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

5 Fluorouracil; Bevacizumab; Colorectal cancer; Irinotecan

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PLACEBO;

ARTICLE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MODELS, STATISTICAL; PLACEBOS; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 53549126631     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000163850     Document Type: Article

References (22)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
2. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712.
3. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Cassidy J: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomised phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). J Clin Oncol 2008;26:2013-2019.
4. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;5:1539-1544.
5. Fyfe GA, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E, Novotny W: Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups (abstract 3617). J Clin Oncol 2004;22(suppl):274s.
6. Yuste AL, Aparicio J, Segura A, Lopez-Tendero P, Girones R, Perez-Fidalgo JA, Diaz R, Calderero V: Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer 2003;2:231-234.
7. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;10:1797-1806.
8. Mitry E, Douillard J-Y, Van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L, Rougier P: Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004;15:1013-1017.
9. Watine J, Friedberg B: Laboratory variables and stratification of metastatic colorectal cancer patients: recommendations for therapeutic trials and for clinical practice guidelines. Clin Chim Acta 2004;345:1-15.
10. Díaz R, Aparicio J, Gironés R, Molina J, Palomar L, Segura A, Montalar J: Analysis of prognostic factors and applicability of Köhne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer 2005;5:197-202.
11. Köhne C-H, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-317.
12. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
13. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
14. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508.
15. Hoff PM: Bevacizumab in older patients and patients with poorer performance status. Semin Oncol 2006;33(5 suppl 10):S19-S25.
16. Díaz R, Aparicio J, Molina J, Palomar L, Ponce J, Segura A, Gomez-Codina J: Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer. Med Oncol 2006;23:347-358.
17. Ray-Coquard I, Pérol D, Bui BNG, Duffaud F, Rios M, Viens P, Robert C, Berthaud P, Le Cesne A, Blay JY: Prognostic factors for progression free and overall survival in advanced GIST: results from the BFR14 phase III trial of the French Sarcoma Group (abstract 9035). J Clin Oncol 2005;23(suppl):824s.
18. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-227.
19. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005;97:981-989.
20. Bendardaf R, Lamlum H, Pyrhönen S: Prognostic and predictive molecular markers in colorectal carcinoma. Anticancer Res 2004;24:2519-2530.
21. Allen WL, Johnston PG: Role of genomic markers in colorectal cancer treatment. J Clin Oncol 2005;23:4545-4552.
22. Mader RM: Links between biology, prognosis and prediction of response to chemotherapy in colorectal cancer. Onkologie 2006;29:334-341.